All Stories

Fierce Pharma Asia—China troubles at Merck, AZ; Astellas' C-suite shuffle and Izervay stumbles

Merck & Co. and AstraZeneca suffered notable losses in China during the fourth quarter. Astellas shuffled its C-suite and revealed a slowdown for its newly launched eye disease med Izervay. Plus more.

Feb 9, 2025 - 21:43
 0
Fierce Pharma Asia—China troubles at Merck, AZ; Astellas' C-suite shuffle and Izervay stumbles
Merck & Co. and AstraZeneca suffered notable losses in China during the fourth quarter. Astellas shuffled its C-suite and revealed a slowdown for its newly launched eye disease med Izervay. Plus more.
Read More

Tags:

Previous Article

Looking ahead at the most anticipated drug launches of 2025

Next Article

Regeneron tangles with Sanofi over commercial transparency in long-running Dupix...

Related Posts

Regulatory tracker: CDC investigates hospitalizations following Valneva's chikungunya vaccine

Regulatory tracker: CDC investigates hospitalizations f...

Feb 28, 2025  0

The Service Edge: The Key to Unlocking the Full Potenti...

Mar 24, 2025  0

Seeking fruitful Lenmeldy launch, Orchard names commercial chief to oversee world’s most expensive drug

Seeking fruitful Lenmeldy launch, Orchard names commerc...

Feb 12, 2025  0